Company: APXIF
Filing Date: 2025-06-13
Form Type: F-4/A
Source: 0001213900-25-054324
Chunk: 358

Company: APx Acquisition Corp. I
Filing Date: 2025-06-13
Form: F-4/A
Chunk 358
---
 available, particularly targeting underserved markets in Latin America. By launching a suite of services and supporting our partners in these regions, we aim to reshape the relationship between consumers, patients, healthcare professionals and providers, and transform healthcare. Our competitive advantage is to include developing market specific end -to -endservices, leveraging both our own and our strategic partners’ laboratories, including local market product adaptation, providing pre- and post -testassessments (technical and commercial onboarding and training) for market co -developmentassistance, and, in certain circumstances, will plan to offer teleconsultations with AI Agents, in addition to consultations with medical geneticists and/or epigenetic specialists to interpret results and accompany in the decision making. We deliver personalized reports and have the necessary operational experience for import and export logistics, as well as the know -howto process and sequence samples effectively. We are also accumulating biological, clinical and lifestyle data across various health fields, enabling us to develop additional innovations. Mission and Strategy We aim to keep people healthy by revolutionizing personal health management, by delivering a comprehensive suite of services spanning prevention, diagnosis and prognosis, integrating a wide range of clinical, biological, and lifestyle data with advanced artificial intelligence, empowering people to make informed health choices and live healthier lives. Our strategy for long -termsustainable expansion is grounded in fundamental drivers that form the core of our business operations. It is our belief that these drivers function collaboratively to reinforce and broad our role in the emerging markets we are developing, which include the following: • Data -driven approach for health management: we are committed to providing preventative health solutions and precise clinical genetic services through our operating segments, Rewell and Heritas Diagnostics. By leveraging technology and data acquisition methods, we are able to train machine learning models that integrate our genetic, microbiome, lifestyle and/or clinical data to deliver more accurate results and foster scientific development. We perform clinical studies under stringent GCP standards to maximize the good quality of our results and comply with the regulatory agencies. We continuously collect diverse omni -modaldata across our product offerings to build robust Latin American genomic data bases. This localized approach addresses the challenges faced other players in the region who rely on foreign markets for sample processing, often resulting in inaccurate outcomes due to the absence of region -specificdata. • Artificial intelligence: from the foundation AI models in genomics to the development of clinically oriented LLMs, we apply algorithms to improve the quality of our results. Through our product offering we plan on providing genomic sequencing, proprietary data processing